1-(4-methylpyridin-3-yl)-6-[(1R,2R)-2-pyrimidin-2-ylcyclobutyl]-5H-pyrazolo[3,4-d]pyrimidin-4-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-(4-methylpyridin-3-yl)-6-[(1R,2R)-2-pyrimidin-2-ylcyclobutyl]-5H-pyrazolo[3,4-d]pyrimidin-4-one
• 化学式: C₁₉H₁₇N₇O
• 分子量: 359.39
• InChiKey: QKQITTYGLPXNKK-CHWSQXEVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  98
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  5-氨基-1-(4-甲基-3-吡啶基)-1H-吡唑-4-甲酰胺 在 sodium hydride 、 乙酰氯 作用下， 以 N-甲基吡咯烷酮 、 乙醇 、 氯仿 、 mineral oil 为溶剂， 反应 14.75h， 生成 1-(4-methylpyridin-3-yl)-6-[(1R,2R)-2-pyrimidin-2-ylcyclobutyl]-5H-pyrazolo[3,4-d]pyrimidin-4-one
  参考文献：
  名称：

  [EN] 6 - CYCLOBUTYL - 1, 5 - DIHYDRO - PYRAZOLO [3, 4-D] PYRIMIDIN- 4 - ONE DERIVATIVES THEIR USE AS PDE9A INHIBITORS
  [FR] DÉRIVÉS DE 6 - CYCLOBUTYL - 1, 5 - DIHYDRO - PYRAZOLO [3, 4-D] PYRIMIDIN- 4 - ONE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE PDE9A

  摘要：

  公开号：

  WO2012110440A9

文献信息

• [EN] 6-CYCLOALKYL-1, 5-DIHYDRO-PYRAZOLO [3, 4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A INHIBITORS<br/>[FR] DÉRIVÉS DE 6-CYCLOALKYL-1,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONE ET LEURS UTILISATIONS EN TANT QU'INHIBITEURS DE PDE9A
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012020022A1

  公开（公告）日：2012-02-16

  The invention relates to novel 6-Cycloalkyl-pyrazolopyrimidinones according to formula (I) wherein R1 is a 5 or 6 membered aromatic heteroaryl-group, R2 is an optional substituent, D is optionally substituted cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl or 2-, 3- or 4-pyridyl, m= 1 or 2 and n is 0, 1 or 2. The new compounds are for use as the active entity of medicaments or for the manufacture of medicaments respectively, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. Such conditions may for example be associated with Alzheimers disease, schizophrenia and other diseases. The new compounds are also for example for the manufacture of medicaments and/or for use in the treatment of these diseases, in particular for cognitive impairment associated with such disease. The compounds of the invention show PDE9 inhibiting properties.

  该发明涉及根据式(I)的新型6-环烷基吡唑吡嘧啶酮，其中R1是5或6成员芳香杂环基团，R2是可选取代基，D是可选取代的环戊基、环己基、四氢呋喃基、四氢吡喃基或2-、3-或4-吡啶基，m=1或2，n为0、1或2。这些新化合物可用作药物的活性成分或用于制造药物，特别是用于治疗涉及感知、注意力、学习或记忆缺陷的疾病的药物。这些疾病可能与阿尔茨海默病、精神分裂症和其他疾病有关。这些新化合物还可用于制造药物和/或用于治疗这些疾病，特别是与此类疾病相关的认知障碍。该发明的化合物显示PDE9抑制特性。
• 6-Cycloalkyl-pyrazolopyrimidinones for the Treatment of CNS Disorders
  申请人：Heine Niklas

  公开号：US20120202829A1

  公开（公告）日：2012-08-09

  The invention relates to novel 6-Cycloalkyl-pyrazolopyrimidinones according to formula (I). wherein R 1 is a 5 or 6 membered aromatic heteroaryl-group, R 2 is an optional substituent, D is optionally substituted cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl or 2-, 3- or 4-pyridyl, m=1 or 2 and n is 0, 1 or 2. The new compounds are for use as the active entity of medicaments or for the manufacture of medicaments respectively, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. Such conditions may for example be associated with Alzheimer's disease, schizophrenia and other diseases. The new compounds are also for example for the manufacture of medicaments and/or for use in the treatment of these diseases, in particular for cognitive impairment associated with such disease. The compounds of the invention show PDE9 inhibiting properties.

  该发明涉及根据式(I)的新型6-环烷基吡唑吡嘧啶酮。 其中R1是5或6成员芳香杂环基团，R2是可选取代基，D是可选取代的环戊基、环己基、四氢呋喃基、四氢吡喃基或2-、3-或4-吡啶基，m=1或2，n为0、1或2。 这些新化合物可用作药物的活性成分或用于制造药物，特别是用于治疗涉及感知、注意力、学习或记忆缺陷的疾病的药物。这些疾病可能与阿尔茨海默病、精神分裂症和其他疾病有关。这些新化合物还可用于制造药物和/或用于治疗这些疾病，特别是与这些疾病相关的认知障碍。该发明的化合物显示PDE9抑制特性。
• 6-CYCLOALKYL-1, 5-DIHYDRO-PYRAZOLO [3, 4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A INHIBITORS
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2603511B1

  公开（公告）日：2017-03-15
• 6-CYCLOBUTYL-1, 5-DIHYDRO-PYRAZOLO [3, 4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A INHIBITORS
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2675807B1

  公开（公告）日：2015-04-22
• 6-CYCLOALKYL-PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF CNS DISORDERS
  申请人：HEINE Niklas

  公开号：US20130040971A1

  公开（公告）日：2013-02-14

  The invention relates to novel pyrazolopyrimidinones according to formula (I) wherein R 1 is a pyridyl or pyrimidinyl group and D is optionally substituted cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl or 2-, 3- or 4-pyridyl. The new compounds are for use as the active entity of medicaments or for the manufacture of medicaments respectively, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. Such conditions may for example be associated with Alzheimer's disease, schizophrenia and other diseases. The new compounds are also for example for the manufacture of medicaments and/or for use in the treatment of these diseases, in particular for cognitive impairment associated with such disease. The compounds of the invention show PDE9 inhibiting properties.